Retosiban - GlaxoSmithKline
Alternative Names: 221149; GSK-221149; GSK-221149ALatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Class Indenes; Morpholines; Oxazoles; Piperazines; Small molecules; Tocolytics
- Mechanism of Action Oxytocin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Preterm labour
Most Recent Events
- 16 Sep 2020 No development reported - Phase-II for Preterm labour in Colombia, Singapore, Puerto Rico (IV)
- 16 Sep 2020 No development reported - Phase-III for Preterm labour (In adolescents, In adults) in USA (IV)
- 16 Sep 2020 No development reported - Phase-III for Preterm labour in South Korea, Mexico, France, United Kingdom, Spain, Italy, Germany, Sweden, Belgium, Israel (IV)